[In today’s special guest essay, Emily Clancy — Executive Managing Editor of Jim Rickards’ Strategic Intelligence — examines the rare hantavirus outbreak now drawing global attention after three deaths aboard a cruise ship.

Emily breaks down what scientists know so far… why health officials are responding so aggressively… and what this outbreak reveals about how the world now reacts to emerging health threats. Read on for her full report.]

Here’s how I first heard about hantavirus: Gene Hackman’s wife.

You know the actor Gene Hackman. To me, he’ll forever be Norman Dale — the hard-nosed basketball coach in Hoosiers, my all-time favorite sports movie.

When Hackman died in February 2025 at age 95, the world mourned a legend. Buried in that story was a quieter tragedy.

His wife, classical pianist Betsy Arakawa, had died roughly a week before him of hantavirus pulmonary syndrome, contracted from infected rodent droppings somewhere in their Santa Fe home.

Hackman, deep in the grip of Alzheimer’s, likely never even knew she was gone.

Most of us filed that event away under “incredibly sad, terribly rare.” Then April 2026 happened.

On April 1, the Dutch expedition ship MV Hondius departed Argentina’s Patagonia carrying 147 passengers and crew on what was supposed to be the adventure of a lifetime. It became something else.

Three passengers died.

By the time the ship docked in Tenerife on May 10 — coordinated with 22 countries and the World Health Organization (WHO) — an international medical relay race was already underway.

Your Rundown for Wednesday, May 13, 2026...

The Next Two Weeks Are Critical

The culprit: Andes virus, a specific hantavirus strain found in the long-tailed pygmy rice rat of Patagonia — and the only hantavirus known to spread from one human being to another.

Human-to-human transmission was first identified during a 1996 outbreak in southern Argentina, and transmission was subsequently documented during the 2018–2019 Epuyén, Argentina outbreak.

A 2023 study out of the Robert Koch Institute, published in Emerging Infectious Diseases, found that infected animals were able to pass the virus to others in close contact — helping explain how an outbreak that began in Patagonia could spread among passengers sharing tight quarters on a ship.

Research published in Frontiers in Cellular and Infection Microbiology further supported the virus replicating in lung tissue and salivary glands, consistent with transmission via respiratory droplets and direct contact.

Unlike many viruses that spread this way, Andes hantavirus pulmonary syndrome carries a fatality rate of roughly 40%.

At the time of writing, the WHO has reported 11 cases tied to the ship, nine confirmed as Andes virus.

What about here at home? So far, no widespread secondary transmission has been identified in the United States.

More than six passengers are being monitored by public health officials in seven states: Arizona, California, Georgia, Texas, Virginia, New Jersey and Maryland. Two Americans are isolated and monitored at Emory University Hospital in Atlanta, while 16 other cruise evacuees remain quarantined in Nebraska.

Should you be scared?

Former FDA Commissioner Dr. Scott Gottlieb has been on every major network since Sunday. On Face the Nationand CNBC’s Squawk Box, he delivered the clearest possible signal: “This is not COVID. [Andes hantavirus] spreads far less efficiently.”

On the absence of any proven treatment, he’s less reassuring: “We don’t have an effective treatment for Hantavirus, and [that’s] what makes this very menacing.”

The good news: Gottlieb noted “the last death on that cruise ship was May 2.” He adds: “I think we’re about two weeks away from knowing whether or not there will be additional cases that come from that initial outbreak on the cruise ship.”

To put this moment in perspective, let’s talk about Ebola.

In 2014, when a small number of Ebola cases reached American soil, the fear was immediate — and largely disproportionate to the real risk to average Americans. But that fear produced something invaluable: urgency.

Finally, Ebola was receiving attention in terms of research and funding. Several vaccines and treatments were fast-tracked for testing and distribution, producing promising results.

These steps forward arrived after years of “low priority,” minimally funded research which, nonetheless, had made significant progress, laying a foundation for rapid advances.

By 2019, the FDA approved the first Ebola vaccine ever.

Two licensed vaccines are now in use for the malignant Zaire ebolavirus strain, protecting communities at risk during outbreaks — where zero existed a decade before.

The research, starved of resources for decades, finally got the funding it needed because the world got scared enough to pay attention.

We may be seeing a familiar pattern emerge again — this time with hantavirus.

Back in January 2020, before most people were thinking seriously about a pandemic, Paradigm’s macro expert Jim Rickards sent a note to his readers titled simply CONTAGION.

He warned that a new pathogen could trigger panic and market disruption. Weeks later, COVID-19 sent markets into the fastest crash in history.

Jim’s core thesis: Rare, high-severity events are routinely underpriced — by markets, by governments and by the public.

But when the world is finally forced to reckon with them, the response, though jarring, often produces lasting improvements in science and preparedness. That dynamic is already at work here.

The Andes virus genome from the Hondius outbreak was posted on the open-access scientific platform Virological.org within days of cruise passengers disembarking — a speed of transparency that would have been unthinkable two decades ago.

And the Robert Koch Institute has already developed a reliable lab-testing system using infected hamsters, giving researchers a faster way to evaluate possible treatments.

The scientific infrastructure, built from the responses to Ebola and COVID, has never been more robust.

There is no approved treatment for hantavirus today. No vaccine. But the machinery to develop both is running hotter than at any point in the virus’s known history.

The bottom line: Three people are dead. This is a real public health event that deserves serious attention.

Yet, the WHO puts global risk at low, with a transmission window that is finite and measurable. Meanwhile, Emory University Hospital — the same facility that successfully treated American Ebola patients in 2014 — is on the case right now.

Watch the next two weeks. Stay reliably informed.

Market Rundown for Wednesday, May 13, 2026

S&P 500 futures are up 0.20% to 7,440.

Oil’s down 0.25% to $101.90 for a barrel of WTI.

Gold is up 0.35% to $4,704 per ounce.

And Bitcoin’s down 0.40% to $80,440.